Qiagen N.V. (NYSE:QGEN) is weighing the sale of a minority stake in its bioinformatics division, which could value that business at more than $1 billion, people familiar with the matter said. The company is working with a financial adviser as it explores bringing in an investor, according to the people. Selling a stake in the unit, which provides software for analyzing biological data, could help fund further growth in this business, the people said.
The deal is likely to attract interest from private equity firms, the people said, asking not to be identified because the information is private. Any transaction would see Qiagen keep a majority stake in the bioinformatics business, which is profitable, the people said. Talks are ongoing and no final decisions have been made.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.